Zacks Investment Research highlights QuidelOrtho (QDEL) as a potentially strong growth stock, noting its 'Hold' rating on the Zacks Rank but an 'A' grade for both Growth and VGM style scores. The company's year-over-year earnings are projected to grow 27% for the current fiscal year, and the consensus earnings estimate for fiscal 2025 has increased to $2.35 per share based on recent upward revisions by analysts; QDEL also has a history of positive earnings surprises, averaging 70.8%.
QuidelOrtho Corporation (QDEL), a key provider of in-vitro diagnostics technologies, currently holds a Zacks Rank #3 (Hold), yet exhibits strong growth characteristics. The company scores an 'A' for its VGM (Value, Growth, Momentum) Style Score and an 'A' for its Growth Style Score, indicating robust underlying fundamentals and future prospects. Notably, QDEL is projected to achieve 27% year-over-year earnings growth for the current fiscal year. Looking ahead to fiscal 2025, the Zacks Consensus Estimate for earnings per share has risen by $0.01 to $2.35, following upward revisions from two analysts in the past 60 days. Furthermore, QDEL has demonstrated a significant historical ability to surpass earnings expectations, with an average earnings surprise of 70.8%. While the #3 Rank suggests a neutral short-term outlook according to Zacks' methodology, the high Growth and VGM scores point to potential upside, particularly for investors prioritizing growth metrics.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
